Souhaitez-vous accéder aux communiqués récents ?

Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”), the event-driven primary disease-free survival (“DFS”) analysis is anticipated...

Announced two-trial clinical development strategy for AKY-2519 enabling evaluation in multiple patient segmentsInitiated Phase 1b clinical trial of AKY-2519 in metastatic castration-resistant prostate...

Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data Natalie Holles appointed Chief Executive Officer and President and member of the Board of Directors ...

Austin, TX, USA, May 11, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Flexible Endoscope Market Size, Trends and Insights By Product (Bronchoscopes,...

Single dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity state (LLDAS) in active SLE Patients; durable B cell remodeling is exhibited by depletion of major...

- Positive pre-BLA meeting completed with FDA for z-rostudirsen in exon 51 DMD; on track for BLA submission in Q2 2026 and potential launch in Q1 2027 - - Positive cardiopulmonary results and...

Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-week maintenance regimen in 1L R/M HPV-negative HNSCC expected to initiate in Q3 2026 Long-term...

Zumilokibart advancing across multiple indications, with Phase 3 initiation in atopic dermatitis (AD) expected later this year:- APEX Phase 2 Part A 52-week data demonstrated durable maintenance and...

First-in-primate data demonstrate in vivo generation of genomic site-specific engineered TRAC-CAR T cells following a single intravenous administration without lymphodepletionAll non-human primates (6...